HilleVaxHLVX
HLVX
About: HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
Employees: 14
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
7% more funds holding
Funds holding: 76 [Q4 2024] → 81 (+5) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 4 (+0) [Q1 2025]
1.92% less ownership
Funds ownership: 86.0% [Q4 2024] → 84.08% (-1.92%) [Q1 2025]
31% less capital invested
Capital invested by funds: $88.7M [Q4 2024] → $61.5M (-$27.2M) [Q1 2025]
33% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 30
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$2
8%
upside
Avg. target
$2
8%
upside
High target
$2
8%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
HC Wainwright & Co. Matthew Caufield | 8%upside $2 | Neutral Reiterated | 31 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
$159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates inadults as well as business development related activities and other strategic alternatives BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2025. First Quarter Financial Results As of March 31, 2025 and December 31, 2024, the company had cash, cash equivalents and marketable securities totaling $159.5 million and $171.4 million, respectively.
Neutral
Business Wire
1 month ago
Frazier Life Sciences Appoints Aditya Kohli to Partner
PALO ALTO, Calif.--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ: HLVX, IPO in 2022), Phathom Pharmaceuticals (NASDAQ: PHAT, IPO in 2019), and Scout Bio (acquired by Ceva Santé Animale). He previously acted.
Neutral
GlobeNewsWire
2 months ago
HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress
$171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2024. Full Year 2024 Financial Results As of December 31, 2024 and December 31, 2023, the company had cash, cash equivalents and marketable securities totaling $171.4 million and $303.5 million, respectively.
Positive
Zacks Investment Research
8 months ago
What Makes HilleVax (HLVX) a New Buy Stock
HilleVax (HLVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
Accesswire
9 months ago
HilleVax, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by HilleVax (HLVX)
NEW YORK, NY / ACCESSWIRE / August 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
Neutral
Accesswire
9 months ago
Levi & Korsinsky Investigates Possible Securities Fraud Violations by HilleVax, Inc. (HLVX)
NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
Neutral
Accesswire
9 months ago
Investors who lost money on HilleVax, Inc. should contact Levi & Korsinsky about an ongoing investigation - HLVX
NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
Neutral
Accesswire
9 months ago
HilleVax, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HLVX
NEW YORK, NY / ACCESSWIRE / August 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
Neutral
Accesswire
9 months ago
ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / August 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
Neutral
Accesswire
9 months ago
ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
Charts implemented using Lightweight Charts™